The release of preliminary results from a proof-of-concept trial is a critical event for biotech companies like Autonomix Medical. Positive results could lead to a significant increase in stock price due to the potential for a new treatment for pancreatic cancer pain, a condition with high unmet medical need. Conversely, negative results could lead to a decline in stock price. Given the high stakes, the news is highly relevant and important for investors.